Search results for " repurposing"
showing 3 items of 13 documents
Life Cycle Assessment of repurposed electric vehicle batteries: an adapted method based on modelling energy flows
2018
Abstract After their first use in electric vehicles (EVs), the residual capacity of traction batteries can make them valuable in other applications. Although reusing EV batteries remains an undeveloped market, second-use applications of EV batteries are in line with circular economy principles and the waste management hierarchy. Although substantial environmental benefits are expected from reusing traction batteries, further efforts are needed in data collection, modelling the life-cycle stages and calculating impact indicators to propose a harmonized and adapted life-cycle assessment (LCA) method. To properly assess the environmental benefits and drawbacks of using repurposed EV batteries …
Vemurafenib Inhibits Acute and Chronic Enterovirus Infection by Affecting Cellular Kinase Phosphatidylinositol 4-Kinase Type IIIβ
2023
Enteroviruses are one of the most abundant viruses causing mild to serious acute infections in humans and also contributing to chronic diseases like type 1 diabetes. Presently, there are no approved antiviral drugs against enteroviruses. Here, we studied the potency of vemurafenib, an FDA-approved RAF kinase inhibitor for treating BRAFV600E mutant-related melanoma, as an antiviral against enteroviruses. We showed that vemurafenib prevented enterovirus translation and replication at low micromolar dosage in an RAF/MEK/ERK-independent manner. Vemurafenib was effective against group A, B, and C enteroviruses, as well as rhinovirus, but not parechovirus or more remote viruses such as Semliki Fo…
Repurposing of the ALK inhibitor crizotinib for acute leukemia and multiple myeloma cells
2021
Crizotinib was a first generation of ALK tyrosine kinase inhibitor approved for the treatment of ALK-positive non-small-cell lung carcinoma (NSCLC) patients. COMPARE and cluster analyses of transcriptomic data of the NCI cell line panel indicated that genes with different cellular functions regulated the sensitivity or resistance of cancer cells to crizotinib. Transcription factor binding motif analyses in gene promoters divulged two transcription factors possibly regulating the expression of these genes, i.e., RXRA and GATA1, which are important for leukemia and erythroid development, respectively. COMPARE analyses also implied that cell lines of various cancer types displayed varying degr…